Wire · opportunities
New weight loss drug retatrutide provides double the weight loss of Ozempic, data shows
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 October 2026 · Fusion42 review
Eli Lilly’s new weight loss drug retatrutide shows more than double the weight loss compared to Ozempic in a phase 3 trial, with additional heart health benefits and improved diabetes markers. Retatrutide, targeting three hunger hormones, is expected for FDA approval submission in early 2027.
This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it between 30 Sep 2026 and 28 Oct 2026.
◆ ◆ The Wire takeaway
You have a new benchmark to beat in weight loss drugs as retatrutide’s triple-hormone approach doubles the effect of top competitors. Expect fast shifts in diabetes and obesity treatments that rewrite the market and regulatory runways.
◆ Coverage
6 sources · first reported 30 Sep 2026 · latest 28 Oct 2026
◆ Related on Wire
◆ Topics